Barinthus Biotherapeutics plc. (BRNS)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.74 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$66.43M

Free cash flow

$48.02M

Return on equity

-89.5%

Return on capital

-75.1%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
26 Jun 2023	Scheeren Joseph Director	Bought	$24.40K	76.9%
25 May 2023	Wright Robin Director	Bought	$36.61K	39.8%
27 Mar 2023	Enright William Chief Executive Officer	Sold at will	$36.30K	2.0%
25 Aug 2022	Ellis Christopher Chief Operating Officer	Sold, plan not stated	$257.40K	99.8%
25 Aug 2022	Griffiths Graham Chief Business Officer	Sold, plan not stated	$73.87K	8.8%
24 Aug 2022	Ellis Christopher Chief Operating Officer	Sold, plan not stated	$2.15K	85.7%

36out of 100

Profitability 39

Financial strength 59

Growth 0

Insiders 50

Strongest on financial strength (59), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan